Mettler Toledo
Mettler Toledo's revenue rose 4.0% to $4.0 billion in fiscal 2025. Its net margin was 21.6%, down from 22.3% a year earlier. Free cash flow was $849 million, down 1.8%. It paid out $800 million in dividends and buybacks, 94% of free cash flow. The diluted share count fell 3.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share grew 12.8% a year and net income 9.5% a year, as buybacks cut the share count by 23%.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Mettler Toledo yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Mettler Toledo's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Mettler Toledo's fiscal 2025 free cash flow of $849M, net cash of −$2.0B at December 31, 2025 and 21 million diluted shares, from its filings. The scenarios are fitted to Mettler Toledo: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 0.9% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 9% for a business of moderate risk (Life Sciences Tools & Services); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $1,669.62
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Mettler Toledo's earnings per share of $44.38 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 37.6×, the middle of Mettler Toledo's own P/E today, its peers' median and its sector's median (Mettler Toledo's own P/E today) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 10%, 9% and 8%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $1,669.62
- Value at this multiple, against the last close
- —
- Mettler Toledo's P/E at the last close
- 37.6×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| IlluminaILMN | $271.04 | $5.36 | 50.6× |
| Bio-Rad LaboratoriesBIO | $372.43 | $7.99 | 46.6× |
| Mettler ToledoMTD | $1,669.62 | $44.38 | 37.6× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 99 | 96 | 70 | 59 | 67 |
| Debt incl. finance leases | 1,581 | 1,908 | 1,889 | 1,837 | 2,105 |
| Net debt (negative means net cash) | 1,482 | 1,812 | 1,819 | 1,778 | 2,038 |
| Net debt to EBITDA | 1.4x | 1.5x | 1.6x | 1.5x | 1.7x |
| Debt to equity | 9.2x | — | — | — | — |
| Interest coverage | 22.9x | 20.3x | 13.6x | 14.9x | 16.3x |
| Current ratio | 1.1x | 1.2x | 1.0x | 1.0x | 1.1x |
| Quick ratio | 0.8x | 0.8x | 0.7x | 0.7x | 0.8x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Mettler Toledo shares on the open market, and 6 insiders sold $35.9 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Patrick KaltenbachPresident and CEO | Sold | 942 | $1,425.00 | $1.3 million | Form 4 |
| Aug 5, 2026 | Thomas P SaliceDirector | Sold | 417 | $1,440.41 | $600,651 | Form 4 |
| Aug 3, 2026 | Shawn VadalaChief Financial Officer | Sold | 2,240 | $1,432.00 | $3.2 million | Form 4 |
| Aug 3, 2026 | Thomas P SaliceDirector | Sold | 415 | $1,444.62 | $599,517 | Form 4 |
| Aug 3, 2026 | Gerry KellerHead of Process Analytics | Sold | 240 | $1,427.14 | $342,514 | Form 4 |
| Feb 10, 2026 | Shawn VadalaChief Financial Officer | Sold | 800 | $1,410.12 | $1.1 million | Form 4 |
| Nov 25, 2025 | la Guerroniere Marc deHead of Eur & NA Market Orgs | Sold | 6,055 | $1,488.18 | $9.0 million | Form 4 |
| Nov 25, 2025 | Shawn VadalaChief Financial Officer | Sold | 1,000 | $1,511.00 | $1.5 million | Form 4 |
| Nov 24, 2025 | Shawn VadalaChief Financial Officer | Sold | 1,025 | $1,452.00 | $1.5 million | Form 4 |
| Nov 21, 2025 | Gerry KellerHead of Process Analytics | Sold | 236 | $1,418.58 | $334,785 | Form 4 |
| Nov 12, 2025 | Patrick KaltenbachPresident and CEO | Sold | 2,000 | $1,462.50 | $2.9 million | Form 4 |
| Nov 11, 2025 | la Guerroniere Marc deHead of Eur & NA Market Orgs | Sold | 6,880 | $1,450.00 | $10.0 million | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 6 of 9 | 7 of 9 | 7 of 9 |
| Accruals ratio | −5.2% | −3.2% | −2.5% |
Compare
Put Mettler Toledo side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Mettler Toledo | FY25 | 4.0% | — | 21.1% | 50.5% | 1.7x | 7 | |
| Charles River Laboratories | FY25 | −0.8% | 0.6% | 12.9% | 0.4% | 4.5x | 4 | Compare |
| Illumina | FY25 | −0.7% | 18.6% | 21.4% | 20.3% | 0.3x | 8 | Compare |
| Waters | FY25 | 7.0% | 25.4% | 17.1% | 21.0% | 0.8x | 6 | Compare |
| Bio-Rad Laboratories | FY25 | 0.7% | 1.8% | 14.5% | 0.5% | −1.6x | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2,508 | 2,725 | 2,936 | 3,009 | 3,085 | 3,718 | 3,920 | 3,788 | 3,872 | 4,026 |
| Revenue growth | 4.7% | 8.6% | 7.7% | 2.5% | 2.5% | 20.5% | 5.4% | −3.4% | 2.2% | 4.0% |
| Gross profit | 1,438 | 1,576 | 1,684 | 1,741 | 1,801 | 2,172 | 2,308 | 2,241 | 2,326 | 2,391 |
| Research and development | 119 | 128 | 141 | 144 | 140 | 170 | 177 | 185 | 189 | 199 |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 384 | 376 | 513 | 561 | 603 | 769 | 872 | 789 | 863 | 869 |
| Diluted EPS (US$) | 14.22 | 14.24 | 19.88 | 22.47 | 24.91 | 32.78 | 38.41 | 35.90 | 40.48 | 42.05 |
| Diluted shares (millions) | 27 | 26 | 26 | 25 | 24 | 24 | 23 | 22 | 21 | 21 |
| Cash flow | ||||||||||
| Cash from operations | 461 | 516 | 565 | 603 | 725 | 909 | 859 | 966 | 968 | 956 |
| Capital expenditure | 124 | 127 | 143 | 97 | 92 | 108 | 121 | 105 | 104 | 107 |
| Free cash flow | 337 | 389 | 422 | 506 | 632 | 801 | 738 | 861 | 864 | 849 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 500 | 400 | 475 | 775 | 775 | 1,000 | 1,100 | 900 | 850 | 800 |
| Acquisitions | 111 | 108 | 6 | 2 | 6 | 221 | 38 | 6 | 10 | 94 |
| Stock-based compensation | 15 | 17 | 18 | 18 | 19 | 20 | 20 | 18 | 20 | 22 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 159 | 149 | 178 | 208 | 94 | 99 | 96 | 70 | 59 | 67 |
| Debt incl. finance leases | 875 | 960 | 985 | 1,235 | 1,284 | 1,581 | 1,908 | 1,889 | 1,837 | 2,105 |
| Total assets | 2,167 | 2,550 | 2,619 | 2,789 | 2,814 | 3,327 | 3,492 | 3,356 | 3,240 | 3,713 |
| Total liabilities | 1,732 | 2,002 | 2,029 | 2,368 | 2,532 | 3,155 | 3,468 | 3,506 | 3,367 | 3,736 |
| Shareholders' equity | 435 | 547 | 590 | 421 | 283 | 171 | 25 | −150 | −127 | −24 |
| Margins and ratios | ||||||||||
| Gross margin | 57.3% | 57.8% | 57.4% | 57.9% | 58.4% | 58.4% | 58.9% | 59.2% | 60.1% | 59.4% |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 15.3% | 13.8% | 17.5% | 18.6% | 19.5% | 20.7% | 22.3% | 20.8% | 22.3% | 21.6% |
| Free cash flow margin | 13.4% | 14.3% | 14.4% | 16.8% | 20.5% | 21.6% | 18.8% | 22.7% | 22.3% | 21.1% |
| Return on capital | 36.8% | 31.7% | 39.2% | 41.6% | 43.4% | 51.4% | 52.6% | 48.6% | 55.7% | 50.5% |
| Return on equity | 75.7% | 76.6% | 90.1% | 111.0% | 171.4% | 338.7% | — | — | — | — |
| Return on assets | 18.6% | 15.9% | 19.8% | 20.8% | 21.5% | 25.0% | 25.6% | 23.0% | 26.2% | 25.0% |
| Net debt to EBITDA | 1.2x | 1.2x | 1.1x | 1.3x | 1.4x | 1.4x | 1.5x | 1.6x | 1.5x | 1.7x |